.

Deeper Knowledge, Faster

  • Plan your formulary budget
  • Find suppliers and generic API sources
  • Obtain formulation and manufacturing information

► See Plans & Pricing

Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving 500+ biopharmaceutical companies globally:

AstraZeneca
Harvard Business School
Baxter
Novartis
Cerilliant
Mallinckrodt
Boehringer Ingelheim
Federal Trade Commission
McKesson
Argus Health

Generated: July 26, 2017

DrugPatentWatch Database Preview

Details for Patent: ► Subscribe

« Back to Dashboard

Details for Patent: ► Subscribe

Title:Controlled release compositions for modulating free-radical induced damage and methods of use thereof
Abstract: Disclosed herein are compositions and methods for the treatment of otic diseases or conditions with free-radical modulating agent compositions and formulations administered locally to an individual afflicted with an otic disease or condition, through direct application of these compositions and formulations onto or via perfusion into the targeted auris structure(s).
Inventor(s): Lichter; Jay (Rancho Santa Fe, CA), Trammel; Andrew M. (Olathe, KS), Piu; Fabrice (San Diego, CA), Ye; Qiang (San Diego, CA), Scaife; Michael Christopher (Los Altos, CA), Vollrath; Benedikt (San Diego, CA), Duron; Sergio G. (San Diego, CA), Dellamary; Luis A. (San Marcos, CA), Lebel; Carl (Malibu, CA), Harris; Jeffrey P. (La Jolla, CA)
Assignee: Otonomy, Inc. (San Diego, CA) The Regents of the University of California (Oakland, CA)
Filing Date:Jul 21, 2009
Application Number:12/506,616
Claims:1. A pharmaceutical composition for treating an otic disease or condition associated with free-radical induced damage, the composition comprising: between about 0.1% to about 10% by weight of a micronized free-radical modulating agent, or pharmaceutically acceptable prodrug or salt thereof; a polyoxyethylene-polyoxypropylene copolymer in an amount sufficient to provide a gelation temperature between about 19.degree. C. to about 42.degree. C., and a gelation viscosity between about 15,000 cP and about 1,000,000 cP; and having less than about 50 colony forming units (cfu) of microbiological agents per gram of composition, wherein the composition provides sustained release of the free-radical modulating agent into the ear for a period of at least 5 days.

2. The pharmaceutical composition of claim 1, wherein the composition provides a practical osmolarity between about 200 and 400 mOsm/L.

3. The pharmaceutical composition of claim 1, wherein the pharmaceutical composition is an auris-acceptable thermoreversible gel.

4. The pharmaceutical composition of claim 1, wherein the composition provides a practical osmolarity between about 250 and 320 mOsm/L.

5. The pharmaceutical composition of claim 1, wherein the free-radical modulating agent is in the form of a neutral molecule, free acid, free base, a salt, a prodrug, or a combination thereof.

6. The pharmaceutical composition of claim 1, wherein the otic disease or condition is ototoxicity, excitotoxicity, sensorineural hearing loss, or presbycusis.

7. A method of alleviating free-radical induced damage associated with an otic intervention comprising administering to an individual in need thereof an intratympanic composition, the composition comprising between about 0.1% to about 10% by weight of a micronized free-radical modulating agent, or pharmaceutically acceptable prodrug or salt thereof; a polyoxyethylene-polyoxypropylene copolymer in an amount sufficient to provide a gelation temperature between about 19.degree. C. to about 42.degree. C., and a gelation viscosity between about 15,000 cP and about 1,000,000 cP; and having less than about 50 colony forming units (cfu) of microbiological agents per gram of composition, wherein the composition provides sustained release of the free-radical modulating agent into the ear for a period of at least 5 days.

8. The pharmaceutical composition of claim 1, wherein the polyoxyethylene-polyoxypropylene copolymer is poloxamer 407.

9. The method of claim 7, wherein the polyoxyethylene-polyoxypropylene copolymer is poloxamer 407.
« Back to Dashboard

For more information try a trial or see the database preview and plans and pricing

Serving 500+ biopharmaceutical companies globally:

Deloitte
Baxter
Accenture
Queensland Health
US Army
Citi
Express Scripts
Johnson and Johnson
Medtronic
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.

Copyright 2002-2017 thinkBiotech LLC
ISSN: 2162-2639

Secure SSL Encrypted Heap | Mobile and Web Analytics

Follow DrugPatentWatch:



Google
Twitter
Google Plus
botpot